Generate Biomedicines

Choose Generate Biomedicines if you're a large pharma or biotech looking to accelerate protein-based drug discovery with a validated generative AI platform. Their 42,000 generated and tested proteins show scale, and GB-0895's Phase 3 status signals clinical credibility. Pass if you're a small academic lab or early-stage startup without significant funding, as their offering seems enterprise-tier. The closest alternative is Recursion Pharmaceuticals, but Generate's focus on generative protein design and its closed-loop platform are distinct advantages. Real-world usage caveats: the platform's capabilities are shown through internal pipeline results, and external validation or API access isn't mentioned. Integration with common bioinformatics tools or cloud providers is not disclosed, so expect a proprietary workflow. Pricing is almost certainly custom and not publicly available.

Generate Biomedicines is a therapeutics company at the intersection of machine learning, biological engineering, and medicine, pioneering generative biology to create breakthrough medicines. The Generate Platform uses generative AI to design novel proteins on demand, moving beyond traditional discovery by leveraging learned rules of protein function. Specific features include the ability to generate and test over 42,000 proteins, a real-time feedback loop between computation and biology, and a focus on multiple therapeutic modalities. The platform aims to fundamentally change how medicines are made, with a current pipeline highlighted by GB-0895, a long-acting anti-TSLP antibody for severe asthma in Phase 3 trials. Unlike traditional drug discovery, Generate's approach compounds learning through continuous experimentation, positioning it as a leader in AI-driven biotherapeutics.